[Duration of antibiotic therapy in febrile neutropenia].

Autor:	Mohamad J; Service de médecine interne générale, Hôpitaux universitaires de Genève, 1211 Genève 14., Grosgurin O; Service de médecine interne générale, Hôpitaux universitaires de Genève, 1211 Genève 14., Leidi A; Service de médecine interne générale, Hôpitaux universitaires de Genève, 1211 Genève 14., Neofytos D; Service des maladies infectieuses, Hôpitaux universitaires de Genève, 1211 Genève 14., Marti C; Service de médecine interne générale, Hôpitaux universitaires de Genève, 1211 Genève 14.
Jazyk:	francouzština
Zdroj:	Revue medicale suisse [Rev Med Suisse] 2023 Oct 25; Vol. 19 (847), pp. 1978-1985.
DOI:	10.53738/REVMED.2023.19.847.1978
Abstrakt:	Febrile neutropenia is a frequent complication of cancer treatment and is associated with an increased risk of morbidity and mortality. However, standardization in the management of neutropenic fever has led to a reduction in its complications. The duration and type of antibiotic therapy differ according to guidelines, particularly in cases of febrile neutropenia of unknown origin. Continuation of antibiotic treatment until resolution of neutropenia has historically been recommended but exposes patients to prolonged periods of broad-spectrum antibiotic therapy. In a context of growing resistance to antibiotics, optimization of antibiotic use is necessary, particularly in this frail patient population, faced with the consequences of repeated exposure to broad-spectrum antibiotic therapy. Competing Interests: Les auteurs n’ont déclaré aucun conflit d’intérêts en relation avec cet article.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu